Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials.
good manufacturing practices
messenger RNA
neoantigens
vaccines
Journal
Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
18
05
2021
revised:
25
08
2021
accepted:
27
08
2021
pubmed:
27
10
2021
medline:
2
2
2022
entrez:
26
10
2021
Statut:
ppublish
Résumé
Messenger RNA (mRNA) has become a promising tool in therapeutic cancer vaccine strategies. Owing to its flexible design and rapid production, mRNA is an attractive antigen delivery format for cancer vaccines targeting mutated peptides expressed in a tumor-the so-called neoantigens. These neoantigens are rarely shared between patients, and inclusion of these antigens in a vaccine requires the production of individual batches of patient-tailored mRNA. The authors have developed MIDRIX
Identifiants
pubmed: 34696961
pii: S1465-3249(21)00778-7
doi: 10.1016/j.jcyt.2021.08.005
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Cancer Vaccines
0
Peptides
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-222Informations de copyright
Copyright © 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article.